AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05042375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab + famitinib
Description: Camrelizumab for injection, 200 mg; Famitinib malate capsules, 20 mg.
Study NCT06348706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptidyl peptidase 4 (DPP-4) inhibitor
Description: Intervention group received Dipeptidyl peptidase-4 (DPP-4) inhibitors supplementation in a dose of 50 mg with main meal for 6 months.
Study NCT04241666 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: renal scintigraphy
Description: Technetium-99m-dimercaptosuccinic acid scintigraphy of both kidneys
Study NCT04241666 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: renal doppler sonography
Description: doppler ultrasound of both kidneys
Study NCT06633211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation using DBBM + Regenfast + collagen matrix
Description: Post extraction sites be filled up to the level of the highest point of the alveolar bone crest using particulate DBBM xenograft (Bio-Oss, Geistlich Pharma AG, Wolhusen, Switzerland) mixed with polynucleotide and hyaluronic acid-based gel (Regenfast®). The alveolus will be sealed with a porcine collagen membrane (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switzerland) and secured with 4-6 simple interrupted sutures (Resolon 6-0, Resorba Medical GmbH, Nuremberg, Germany).
Study NCT06633211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation using DBBM + collagen matrix
Description: Post extraction sites be filled up to the level of the highest point of the alveolar bone crest using particulate DBBM xenograft (Bio-Oss, Geistlich Pharma AG, Wolhusen, Switzerland). The alveolus will be sealed with a porcine collagen membrane (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switzerland) and secured with 4-6 simple interrupted sutures (Resolon 6-0, Resorba Medical GmbH, Nuremberg, Germany).
Study NCT05460572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Peripheral Parental Nutrition
Description: Peripheral parenteral nutrition (PPN) through an intravenous (iv) line
Study NCT04619719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT)
Description: Patients assigned to the treatment arm will receive up to 5 treatments of hyperbaric oxygen therapy administered daily at 2.0 atmospheres for 90 minutes per session.
Study NCT05023382 — intervention group
Intervention type: DRUG
Intervention: Teduglutide
Description: Teduglutide 0.05 mg/kg SC injection
Study NCT06532253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVDX3
Description: NVDX3 is implanted during a single surgical intervention, that took place in the core trials (refer to NCT05961956 and NCT05987033)
Study NCT06248541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treatment with low-level laser therapy
Description: low-level laser therapy (wavelength of 620 - 640nm)
Study NCT06248541 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: treatment with conventional light diodes
Description: conventional light diodes
Study NCT04738474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Resilience in Stress Management (PRISM)
Description: Develops personal resilience resources through 1:1 sessions with a PRISM coach.
Study NCT04738474 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: No additional study-specific interaction with subjects. Subjects continue to receive usual medical care.
Study NCT05042375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab 200 mg.
Study NCT05042375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Camrelizumab for injection, 200 mg.
Study NCT05507645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Prourokinase for Injection (rhPro-UK)
Description: 15mg of rhPro-UK intravenous bolus within 3 minutes, and the remaining 20mg intravenous drip within 30 minutes.
Study NCT05507645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard medical treatment
Description: Standard antiplatelet or anticoagulant treatment at the discretion of local investigators.
Study NCT06445634 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gonioscopy-Assisted Transluminal Trabeculotomy Combined with Goniosynechiolysis
Description: Gonioscopy-Assisted Transluminal Trabeculotomy Combined with Goniosynechiolysis in Glaucoma Patients with Secondary Synechial Angle Closure
Study NCT05267535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piromelatine 20 mg
Description: Tablets
Study NCT05267535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study NCT05792163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNP318 (A)
Description: Capsule for oral administration
Study NCT05792163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (B)
Description: Placebo capsules matching the SNP318 capsules
Study NCT06386211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAGNE-B6 Oral Solution
Description: Oral solution.
Study NCT06386211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAGNE-B6 New Formulation Tablet
Description: New formulation tablet.
Study NCT04882631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-100 Topical Cream
Description: A dose of approximately 560 ug (approximately 0.4 mL of each of the three concentrations to 3 different sites) of PBI-100 was applied daily (excluding weekends) to the skin test sites.
Study NCT04882631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positive Control - Sodium laurel sulfate (SLS)
Description: Approximately 0.4 mL of 0.25% SLS was applied daily (excluding weekends) as a positive control test site.
Study NCT04882631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBI-100 Topical Cream, Vehicle
Description: Approximately 0.4 mL of 0% placebo cream was applied daily (excluding weekends) as a positive control test site.
Study NCT04882631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative Control
Description: A blank patch was applied daily (excluding weekends) as a negative control test site.
Study NCT06049836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Holograms
Description: Clinical decision making based on visualising liver 3D holographic augmented reality liver models
Study NCT06049836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDF
Description: Clinical decision making based on visualisation of 3D liver rendering on computer monitors on a PDF file
Study NCT04406597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the New Tissue Containment System
Description: Laparoscopic Ovarian Cystectomy using the New Tissue Containment System
Study NCT04682730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deliberative Loop
Description: The investigators will give background information to the stakeholders before they engage in the Deliberative session.~Stakeholders from a given clinic will come together for a Deliberative session (i.e., facilitated conversation), enabling them to hear the full range of perspectives held by their fellow colleagues and to share their own perspective regarding how best to implement the guideline in small-group discussions.~Following the Deliberative session, each stakeholder will have the opportunity to record their opinions regarding possible implementation interventions. The investigators will share these opinions with the clinic's decision-makers to help guide their decision-making about which implementation interventions to deploy. If a stakeholder happens to be absent the day of their clinic's Deliberative session, they will still have the opportunity to complete the survey.
Study NCT05960318 — intervention group
Intervention type: DEVICE
Intervention: KalobaNaso spray
Description: Nasal spray, 2 puff per nostril, 3 times a day
Study NCT05960318 — intervention group
Intervention type: DEVICE
Intervention: KalobaNaso junior spray
Description: Nasal spray, 1 puff per nostril, 3 times a day
Study NCT05243979 — intervention group
Intervention type: RADIATION
Intervention: DEXA scan
Description: bone study
Study NCT05750108 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parasym device (active, current (mA) < discomfort threshold)
Description: Active transcutaneous Vagal Nerve Stimulation (tVNS) (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to the ear at 20 hertz (Hz), 250 microseconds (ms) at a current just below discomfort threshold for 30 minutes twice a day, starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
Study NCT05750108 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Parasym device (sham, current (mA) = 0)
Description: Parasym device will be attached to the ear twice a day, turned on but current set to 0 milliamp (mA), starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
Study NCT05474456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNAGs
Description: Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
Study NCT05474456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manipulation
Description: Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
Study NCT05832099 — intervention group
Intervention type: RADIATION
Intervention: Radiation
Description: The techniques of conformal focal-brain irradiation in the era of modern radiotherapy (i.e., conventionally fractionated VMAT, hypofractionated stereotactic radiotherapy, and proton beam therapy, etc)
Study NCT04906083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Avatrombopag:~PLT：30\~50×10\^9/L patients, 40 mg/d; PLT：\<30×10\^9/L patients, 60 mg/d.
Study NCT04906083 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard medical treatment
Description: Standard medical treatment included transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al.
Study NCT04796129 — intervention group
Intervention type: OTHER
Intervention: the patients with hip osteoarthritis and their inflammatory status
Description: The participants in the experimental group will be evaluated for the hip osteoarthritis. They will take and X-ray for hip joints and also hemogram for the excluding the inflammatory diseases.
Study NCT04306458 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive esophagectomy
Description: Conventional minimally invasive esophagectomy
Study NCT04306458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy
Description: Conventional minimally invasive esophagectomy
Study NCT04306458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: daVinci Xi system
Description: robot assisted minimally invasive esophagectomy
Study NCT06460038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Inhibitor of NH3
Study NCT06460038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug
Study NCT05707338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy with lymph node dissection
Description: prospective randomized comparative clinical trial study analyzing outcomes of gastrectomy for early gastric cancer using laporoscopy versus open approach. This will be a prospective comparative study at Sohag University Hospital, Egypt and National Cancer Institute(NCI), Cairo university ,Egypt.~Patients were divided randomizly into two groups; the first group included patients who will have laparoscopic gastrectomy (Lap group), and the second group included patients will receive open gastrectomy (Open group).
Study NCT05326607 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prototype of adaptive eyeglasses
Description: The tested investigational medical device is a prototype of semi-integrated eyeglasses.
Study NCT05326607 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Comparator
Description: The comparator is either a pair of progressive lenses that provide clear vision at both distance and near vision, either, for wearers who have rejected progressive glasses, an alternative solution providing clear vision at both distance and near vision which can consist of bifocal glasses, multifocal or monovision lenses, multiple pairs of glasses or one pair for cases of emmetropia.
Study NCT04906083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Description: Standard medical treatment included transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al.
Study NCT05778552 — intervention group
Intervention type: DEVICE
Intervention: Home-based pelvic muscle training devices or traditional PFMT at hospital
Description: Performed home-based pelvic muscle training devices at home or traditional PFMT at hospital
Study NCT04551430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib will be supplied by Exelixis.
Study NCT04551430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.
Study NCT04551430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.
Study NCT06394843 — intervention group
Intervention type: OTHER
Intervention: Ultrafiltration
Description: Patients are selected depending on need of ultrafiltration
Study NCT05082064 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: arterial blood gases and serum electrolytes
Description: arterial bloog gases parameters serum potassium serum sodium serum calcium
Study NCT05276882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: It will be an individualized hypnosis session of Ericksonian type. It consists in going through 3 phases: induction, dissociation, suggestion.~The principle is to focus the patient's attention by talking to her or by surprising her, or by making her do an incongruous gesture which will make her focus on a restricted idea. She will reduce her field of consciousness and concentrate. This is where her work will begin, allowing her unconscious to function in order to find her solutions. At this moment, she is particularly receptive to suggestions and the hypnotherapist accompanies and guides her thoughts and her associations of ideas on therapeutic paths. He provokes a unique personal work which aims to promote healing.
Study NCT05276882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pre-surgery consultation
Description: Dialogue with the patient to clarify her expectations.~* Answers to the patient's questions~* Precision on the organization of the hospitalization if necessary~* Information on the postoperative period with postural advice to facilitate the first getting up with less discomfort, and postures promoting rest in the postoperative period~* Information on relaxation techniques and their interest (abdominal breathing)
Study NCT04919863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTP42:KVA4
Description: Single ascending dose (SAD) or multiple ascending dose (MAD) of NTP42:KVA4 administered to healthy volunteers as an oral suspension.
Study NCT04919863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, matched to corresponding doses of NTP42:KVA4 administered to healthy volunteers as an oral solution.
Study NCT05295238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compass Course
Description: An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
Study NCT05061186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistive Expiratory muscle Training Group
Description: Mild Resistive Expiratory Technique \[Expiratory Muscle Strength Training (EMST150)- six-week training protocol approximately 20 min per day\] The EMST requires the participant to forcibly blow into the device for 5 seconds with sufficient pressure to open the one-way valve. Each blow is one repetition. The device will be set at a resistance of 30 cmH2O. Participants will be instructed to complete five sets of five repetitions (total of 25 times and approximately 20 minutes per day), any five days per week, for six weeks. Whole exercise will be done in sitting position. Rest between repetitions will be given according to comfort level of patient.
Study NCT05061186 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Breathing Exercise Group
Description: Breathing Exercises: (approximately 20 minutes per day)~● Pursed lip breathing: (Sit with your back straight. Inhale through your nose for two seconds. Purse your lips like you're blowing on hot food and then breathe out slowly, taking twice as long to exhale as you took to breathe in. 4-5 times a day)~● Diaphragmatic breathing: (Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs. Breathe in slowly through your nose Tighten your stomach muscles, letting them fall inward as you exhale through pursed lips. Practice this exercise 5-10 minutes about 3-4 times per day).~● Incentive spirometer: (Hold in an upright position. Breathe in slowly and as deeply as possible. Hold your breath as long as possible (at least for 5 seconds). Then exhale slowly Rest for a few seconds and at least 10 times every hour)
Study NCT06152952 — intervention group
Intervention type: PROCEDURE
Intervention: The rhomboid flap approach
Description: The rhomboid flap Approach :~The flap will be dissected deep to the gluteal fascia (subfascial level) so as to raise thick a fasciocutaneous flap. This will assure good vascularity of the flap without dead space. The rhomboid flap (CDEF) will be mobilized from the gluteal fascia and sutured without tension in three layers~The deep suturing approach :~A vertical elliptical incision encompassing all pilonidal pits will be made and excision of the sinus will be carried out down to the level of the sacrococcygeal fascia. T then the deep fascia will be approximated and the wound will be closed
Study NCT06283576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid biopsy
Description: Blood will be drawn upon clinical diagnosis / prior to biopsy/surgical resection for ground truth
Study NCT04863222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: During a patients procedure, one tooth will receive Biodentine instead of MTA.
Study NCT04863222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mineral trioxide aggregate (MTA)
Description: mineral trioxide aggregate (MTA)
Study NCT05135052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhenium-SCT
Description: Rhenium-SCT irradiation device
Study NCT04739527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCP-001
Description: allogeneic dendritic cell vaccine
Study NCT06210438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921 + Bevacizumab
Description: SHR-A1921 + Bevacizumab
Study NCT04873765 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgastrim Megalabs
Description: Administration of 6 mg of Pegfilgrastim Megalabs subcutaneous single dose
Study NCT04873765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgastrim Megalabs
Description: Administration of 6 mg of Pegfilgrastim Megalabs subcutaneous single dose
Study NCT04873765 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgastim Amgen
Description: Administration of 6 mg of Pegfilgrastim Amgen subcutaneous single dose
Study NCT04873765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgastim Amgen
Description: Administration of 6 mg of Pegfilgrastim Amgen subcutaneous single dose
Study NCT05827835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD7 CAR-T cells injection
Description: CD7 CAR T cells treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
Study NCT05827835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Description: In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
Study NCT05506410 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: Young patients (\< 65 years of age) were treated with R-BAP for 6 cycles (efficacy was assessed every 2 cycles, and adverse events were recorded), together with oral ibrutinib, followed by oral ibrutinib for 1 year after chemotherapy (efficacy was assessed every 3 months). Elderly patients (≥65 years of age) received 4 cycles of R-BAP (efficacy assessed every 2 cycles, and adverse reactions recorded), followed by 4 cycles of rituximab consolidation (efficacy assessed every 2 cycles) and 1 year of oral zanubrutinib (efficacy assessed every 3 months).
Study NCT05795738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chinese character-based visuomotor training program
Description: this program includes visual-perceptual-motor play, paper-pencil activities, and ipad games using Chinese character as activity materials